Implementing a molecular prescreening strategy for tumors without public NGS access in a cancer center network: Results from the PREICO project


Por: Sàbat, P, Ajenjo-Bauza, M, Hierro, C, Ruffinelli, JC, Gil-Martin, M, Ochoa-de-Olza, M, Bergamino, M, Calvo, M, Soto-Castillo, JJ, Fina, C, Llop, S, Stradella, A, Oliva, M, Notario, L, Carcereny, E, Teixidor-Vilà, E, Domènech, M, Jové, M, Villanueva, R, Alay, A, Azuara, D, González-Acosta, M, Otero-Torres, S, Gausachs, M, Varela, M, Villatoro, S, Solanes, A, Teulé, A, Cuadra, C, Moreno, V, Nadal, E, Cordero, D, Lázaro, C and Martin-Liberal, J

Publicada: 15 may 2026 Ahead of Print: 1 abr 2026
Resumen:
Background: Next-generation sequencing (NGS) is central to precision oncology. However, its implementation in public healthcare systems is limited by economic and logistical barriers. In 2022, the Catalan Institute of Oncology (ICO) launched the PREICO project to expand access to comprehensive genomic profiling (CGP) beyond publicly funded indications across a cancer center network. Methods: We analyzed patients with advanced solid tumors, enrolled between February 2022 and March 2024. Molecular results were reviewed by a Molecular Tumor Board (MTB), which issued structured reports to support clinical decision-making. Results: CGP was performed in 249 patients. At least one pathogenic or likely pathogenic alteration was identified in 96.3% of 242 evaluable samples. High tumor mutational burden (TMB >= 10 mut/Mb, TMB-H) was detected in 15.3% and microsatellite instability (MSI) in 1.7%. Overall, 47 tumor-agnostic ESCAT I actionable biomarkers were detected, including MSI, TMB-H, BRAF V600E mutation, and NTRK and FGFR fusions. 25 patients received NGS-matched therapies (10.3% of the cohort; 19% of treated patients), 56% within earlyphase clinical trials, and 44% through compassionate use. Objective response rate was 20%, and clinical benefit rate (CR, PR, or SD>4 months) was 40%. Median progression-free survival and overall survival were 3.3 and 11.4 months, respectively. Conclusions: The PREICO project suggests the feasibility of implementing a centralized CGP prescreening program in a public healthcare setting for tumor types without public NGS access. CGP identified potentially actionable alterations in a substantial proportion of patients across tumor types, informed treatment decisions and facilitated access to clinical trials in selected cases.

Filiaciones:
Sàbat, P:
 Catalan Inst Oncol ICO Hosp, Med Oncol Dept, LHospitalet Llobregat, Barcelona, Spain

Ajenjo-Bauza, M:
 Inst Catala Oncol, Unit Bioinformat Precis Oncol, LHospitalet Llobregat, Barcelona, Spain

 Inst Invest Biomed Bellvitge IDIBELL, ONCOBELL Program, Preclin & Expt Res thorac tumors PRETT Grp, LHospitalet Llobregat, Spain

:
 Univ Autonoma Barcelona UAB, Catalan Inst Oncol ICO Badalona, CARE IGTP Germans Trias i Pujol Inst, Badalona Appl Res Grp Oncol B ARGO,Med Oncol Dept, Badalona, Barcelona, Spain

Ruffinelli, JC:
 Catalan Inst Oncol ICO Hosp, Med Oncol Dept, LHospitalet Llobregat, Barcelona, Spain

Gil-Martin, M:
 Catalan Inst Oncol ICO Hosp, Med Oncol Dept, LHospitalet Llobregat, Barcelona, Spain

:
 Univ Autonoma Barcelona UAB, Catalan Inst Oncol ICO Badalona, CARE IGTP Germans Trias i Pujol Inst, Badalona Appl Res Grp Oncol B ARGO,Med Oncol Dept, Badalona, Barcelona, Spain

:
 Univ Autonoma Barcelona UAB, Catalan Inst Oncol ICO Badalona, CARE IGTP Germans Trias i Pujol Inst, Badalona Appl Res Grp Oncol B ARGO,Med Oncol Dept, Badalona, Barcelona, Spain

Calvo, M:
 Catalan Inst Oncol ICO Hosp, Med Oncol Dept, LHospitalet Llobregat, Barcelona, Spain

Soto-Castillo, JJ:
 Catalan Inst Oncol ICO Hosp, Med Oncol Dept, LHospitalet Llobregat, Barcelona, Spain

 START Madrid CIOCC Hosp Univ HM Sanchinarro, Madrid, Spain

Fina, C:
 Doctor Josep Trueta Univ Hosp, Catalan Inst Oncol ICO Girona, Girona BiomedicaI Res Inst IDIBGI CERCA, Med Oncol Dept, Girona, Girona, Spain

 Girona BiomedicaI Res Inst IDIBGI CERCA, Parc Hosp Marti i Julia, Precis Oncol Grp OncoGIR Pro, Girona, Spain

Llop, S:
 Catalan Inst Oncol ICO Hosp, Med Oncol Dept, LHospitalet Llobregat, Barcelona, Spain

Stradella, A:
 Catalan Inst Oncol ICO Hosp, Med Oncol Dept, LHospitalet Llobregat, Barcelona, Spain

Oliva, M:
 Catalan Inst Oncol ICO Hosp, Med Oncol Dept, LHospitalet Llobregat, Barcelona, Spain

:
 Univ Autonoma Barcelona UAB, Catalan Inst Oncol ICO Badalona, CARE IGTP Germans Trias i Pujol Inst, Badalona Appl Res Grp Oncol B ARGO,Med Oncol Dept, Badalona, Barcelona, Spain

:
 Univ Autonoma Barcelona UAB, Catalan Inst Oncol ICO Badalona, CARE IGTP Germans Trias i Pujol Inst, Badalona Appl Res Grp Oncol B ARGO,Med Oncol Dept, Badalona, Barcelona, Spain

Teixidor-Vilà, E:
 Doctor Josep Trueta Univ Hosp, Catalan Inst Oncol ICO Girona, Girona BiomedicaI Res Inst IDIBGI CERCA, Med Oncol Dept, Girona, Girona, Spain

 Girona BiomedicaI Res Inst IDIBGI CERCA, Parc Hosp Marti i Julia, Precis Oncol Grp OncoGIR Pro, Girona, Spain

:
 Univ Autonoma Barcelona UAB, Catalan Inst Oncol ICO Badalona, CARE IGTP Germans Trias i Pujol Inst, Badalona Appl Res Grp Oncol B ARGO,Med Oncol Dept, Badalona, Barcelona, Spain

Jové, M:
 Catalan Inst Oncol ICO Hosp, Med Oncol Dept, LHospitalet Llobregat, Barcelona, Spain

Villanueva, R:
 Catalan Inst Oncol ICO Hosp, Med Oncol Dept, LHospitalet Llobregat, Barcelona, Spain

Alay, A:
 Inst Catala Oncol, Unit Bioinformat Precis Oncol, LHospitalet Llobregat, Barcelona, Spain

 Inst Invest Biomed Bellvitge IDIBELL, ONCOBELL Program, Preclin & Expt Res thorac tumors PRETT Grp, LHospitalet Llobregat, Spain

Azuara, D:
 Catalan Inst Oncol ICO Hospitalet, Hereditary Canc Program, LHospitalet Llobregat, Barcelona, Spain

 Bellvitge Biomed Res Inst IDIBELL ONCOBELL, Mol Mech & Expt Therapy Oncol Program, LHospitalet Llobregat, Barcelona, Spain

 Inst Salud Carlos III, Ctr Invest Biomed Red Canc CIBERONC, Madrid, Spain

González-Acosta, M:
 Catalan Inst Oncol ICO Hospitalet, Hereditary Canc Program, LHospitalet Llobregat, Barcelona, Spain

 Bellvitge Biomed Res Inst IDIBELL ONCOBELL, Mol Mech & Expt Therapy Oncol Program, LHospitalet Llobregat, Barcelona, Spain

 Inst Salud Carlos III, Ctr Invest Biomed Red Canc CIBERONC, Madrid, Spain

Otero-Torres, S:
 Catalan Inst Oncol ICO Hospitalet, Pharm Dept, LHospitalet Llobregat, Barcelona, Spain

Gausachs, M:
 Catalan Inst Oncol ICO Hosp, Med Oncol Dept, LHospitalet Llobregat, Barcelona, Spain

 Inst Invest Biomed Bellvitge IDIBELL, ONCOBELL Program, Preclin & Expt Res thorac tumors PRETT Grp, LHospitalet Llobregat, Spain

Varela, M:
 Hosp Univ Bellvitge, Dept Pathol, LHospitalet Llobregat, Barcelona, Spain

 Hosp Univ Bellvitge, Inst Catala dOncol, Lab Core dAnalisi Mol, LHospitalet Llobregat, Barcelona, Spain

Villatoro, S:
 Hosp Univ Bellvitge, Dept Pathol, LHospitalet Llobregat, Barcelona, Spain

 Hosp Univ Bellvitge, Inst Catala dOncol, Lab Core dAnalisi Mol, LHospitalet Llobregat, Barcelona, Spain

Solanes, A:
 Catalan Inst Oncol ICO Hospitalet, Hereditary Canc Program, LHospitalet Llobregat, Barcelona, Spain

Teulé, A:
 Catalan Inst Oncol ICO Hospitalet, Hereditary Canc Program, LHospitalet Llobregat, Barcelona, Spain

Cuadra, C:
 Catalan Inst Oncol ICO Hosp, Med Oncol Dept, LHospitalet Llobregat, Barcelona, Spain

Moreno, V:
 Inst Catala Oncol, Unit Bioinformat Precis Oncol, LHospitalet Llobregat, Barcelona, Spain

 Inst Invest Biomed Bellvitge IDIBELL, ONCOBELL Program, Preclin & Expt Res thorac tumors PRETT Grp, LHospitalet Llobregat, Spain

 Consorcio Invest Biomed Red Epidemiol & Salud Publ, Madrid, Spain

 Univ Barcelona UB, Fac Med & Hlth Sci, Dept Clin Sci, LHospitalet Llobregat, Barcelona, Spain

 Univ Barcelona UB, Univ Barcelona Inst Complex Syst UBICS, LHospitalet Llobregat, Barcelona, Spain

Nadal, E:
 Catalan Inst Oncol ICO Hosp, Med Oncol Dept, LHospitalet Llobregat, Barcelona, Spain

 Inst Invest Biomed Bellvitge IDIBELL, ONCOBELL Program, Preclin & Expt Res thorac tumors PRETT Grp, LHospitalet Llobregat, Spain

 Univ Barcelona UB, Fac Med & Hlth Sci, Dept Clin Sci, LHospitalet Llobregat, Barcelona, Spain

Cordero, D:
 Inst Catala Oncol, Unit Bioinformat Precis Oncol, LHospitalet Llobregat, Barcelona, Spain

 Inst Invest Biomed Bellvitge IDIBELL, ONCOBELL Program, Preclin & Expt Res thorac tumors PRETT Grp, LHospitalet Llobregat, Spain

Lázaro, C:
 Catalan Inst Oncol ICO Hospitalet, Hereditary Canc Program, LHospitalet Llobregat, Barcelona, Spain

 Bellvitge Biomed Res Inst IDIBELL ONCOBELL, Mol Mech & Expt Therapy Oncol Program, LHospitalet Llobregat, Barcelona, Spain

 Inst Salud Carlos III, Ctr Invest Biomed Red Canc CIBERONC, Madrid, Spain

Martin-Liberal, J:
 Catalan Inst Oncol ICO Hosp, Med Oncol Dept, LHospitalet Llobregat, Barcelona, Spain
ISSN: 09598049





European Journal of Cancer
Editorial
Elsevier Ltd., THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND, Reino Unido
Tipo de documento: Article
Volumen: 239 Número:
Páginas:
WOS Id: 001743947500001
ID de PubMed: 41962211

MÉTRICAS